Singapore markets closed

Precision BioSciences, Inc. (DTIL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6000-0.0800 (-4.76%)
As of 10:47AM EDT. Market open.

Precision BioSciences, Inc.

302 East Pettigrew Street
Suite A-100
Durham, NC 27701
United States
919 314 5512
https://www.precisionbiosciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees190

Key executives

NameTitlePayExercisedYear born
Mr. Michael AmorosoPres, CEO & Director876.24kN/A1979
Dr. Derek Jantz Ph.D.Co-Founder, Chief Scientific Officer & Director597.38kN/A1976
Mr. John Alexander KellyChief Financial Officer691.14kN/A1967
Dr. Jefferson J. Smith Ph.D.Co-Founder & CTON/AN/AN/A
Mr. Shane BartonVP, Corp. Controller & Principal Accounting OfficerN/AN/A1971
Mr. Dario ScimecaGen. Counsel & Sec.N/AN/A1975
Mr. Bruce StevensVP of Quality & ComplianceN/AN/AN/A
Ms. Heather KingDirector of Marketing Communications & PRN/AN/AN/A
Maurissa MessierSr. Director of Corp. CommunicationsN/AN/AN/A
Ms. Dawn LosingerActing Head of HR Director, Talent Acquisition & ManagementN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Corporate governance

Precision BioSciences, Inc.’s ISS governance QualityScore as of 1 May 2022 is 8. The pillar scores are Audit: 3; Board: 9; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.